HB Wealth Management LLC Acquires New Shares in Immunic, Inc. (NASDAQ:IMUX)

HB Wealth Management LLC bought a new position in Immunic, Inc. (NASDAQ:IMUX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 78,400 shares of the company’s stock, valued at approximately $81,000. HB Wealth Management LLC owned 0.09% of Immunic at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in IMUX. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the period. Jane Street Group LLC grew its position in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at approximately $50,000. Finally, State Street Corp raised its holdings in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on IMUX shares. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a research note on Tuesday, January 7th. Finally, HC Wainwright started coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $12.67.

Insider Buying and Selling

In other news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.00% of the company’s stock.

Immunic Stock Up 2.8 %

NASDAQ:IMUX opened at $1.02 on Friday. The business’s 50-day moving average price is $1.10 and its 200 day moving average price is $1.31. Immunic, Inc. has a 52-week low of $0.92 and a 52-week high of $2.11. The firm has a market cap of $91.88 million, a P/E ratio of -0.83 and a beta of 1.88.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). During the same quarter in the prior year, the company posted ($0.51) EPS. Sell-side analysts expect that Immunic, Inc. will post -0.94 EPS for the current year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.